Print Page  Close Window

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
September 19, 2017
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
Dimension to Begin Discussions with Ultragenyx CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX), a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, announced today that its Board of Directors has determined in good faith, after consultation with its financial advisor and outside legal counsel, that the non-binding, unsolicited proposal from Ultr[...]  Read More /
September 18, 2017
Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
CAMBRIDGE, Mass., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (Nasdaq:DMTX) (“Dimension”), a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, today confirmed that it has received a non-binding, unsolicited proposal from Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) (“Ultragenyx”) to acquire Dimension for $5.50 per share in cash to be effectuated via a tender offer. Ultragen[...]  Read More /
August 31, 2017
Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency
Twelve trial sites recruiting patients with OTC deficiency in the United States, United Kingdom, Spain, and Canada Initial data from the company’s Phase 1/2 study anticipated by late 2017 CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced the initiation of patient dosing in the company’s [...]  Read More /
August 25, 2017
REGENXBIO to Acquire Dimension Therapeutics
Acquisition will add two lead product candidates to REGENXBIO’s metabolic disease franchise: - DTX301 for OTC deficiency, being studied in an on-going Phase I/II clinical trial - DTX401 for GSDIa, a late-stage preclinical candidate with an anticipated IND filing in early 2018 Acquisition will enhance REGENXBIO’s pipeline of gene therapy product candidates, with the potential to achieve multiple milestones through the end of 2018 REGENXBIO will host a conference call this mor[...]  Read More /
August 08, 2017
Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A programs expected in early 2018 CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today reported financial results for t[...]  Read More /
July 24, 2017
Dimension Therapeutics Announces Management Change
CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that Jean Franchi, Chief Financial Officer, has resigned in order to pursue other opportunities, effective July 28, 2017.  "The Board and I wish to express our thanks to Jean for her contributions and service to Dimension's leadership team[...]  Read More /
June 27, 2017
Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities
Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A expected in 2018 Operating expenses reduced and cash runway extended CAMBRIDGE, Mass., June 27, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, t[...]  Read More /
May 10, 2017
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector IMD product candidate for OTC Deficiency, expected 2H 2017 CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key o[...]  Read More /
April 24, 2017
Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced poster presentations that highlight technology underpinning select product candidate programs. The presentations will occur during the 20th ASGCT Annual Meeting, which is taking place in Washington, DC, May 10-13, 2017. “We are pleased th[...]  Read More /
March 09, 2017
Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
In December, initiated Phase 1/2 clinical trial of DTX301, Dimension’s lead IMD product candidate for OTC Deficiency; Initial data expected 2H 2017 Updates interim results from Phase 1/2 clinical program for DTX101 in hemophilia B Conference call today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key [...]  Read More /
March 07, 2017
Dimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call
CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that it will report financial results for the full year ended December 31, 2016, on Thursday, March 9, 2017. Following distribution of the earnings release via wire services, Dimension Therapeutics will host a live conference call and webcas[...]  Read More /
February 07, 2017
Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced the election of John A. Hohneker, M.D., Executive Vice President, Head of Research and Development of FORMA Therapeutics Inc., to Dimension’s Board of Directors (the “Board”). Dr. Hohneker brings over 25 years’ global experience in pharmaceut[...]  Read More /
January 31, 2017
Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
Evidence of High-Efficiency Liver Transduction with AAVrh10 Vector Sub-clinical, Asymptomatic Elevations of ALT Observed in 5 of 6 Patients CAMBRIDGE, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced preliminary topline safety and early efficacy results of Dimension’s multi-center phase 1/2 study[...]  Read More /